Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?
Lilly(LLY) The Motley Fool·2024-08-29 09:44Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem.If the price is right, sales can soar. That's true with any product -- even prescription drugs.On Tuesday, Eli Lilly (LLY -0.58%) announced a new pricing plan for its latest blockbuster drug, Zepbound. The therapy will now be available to self-pay patients at a 50% or greater discount to the list price of other GLP-1 obesity drugs. Is Lilly stock a no-brainer buy after the company's Zepbound move? Why Li ...